| Institution: | 1. ARCAGY-GINECO, Paris, France;2. Saitama Medical University International Medical Center, Hidaka, Saitama, Japan;3. University College London Cancer Institute, London, UK;4. University College London Hospitals, London, UK;5. Princess Margaret Cancer Centre, Toronto, ON, Canada;6. Centre Léon Bérard, Service de Cancérologie Médicale, Université Claude Bernard Lyon 1, Lyon, France;7. Groupe d''Investigateurs Nationaux pour l''Etude des Cancers Ovariens (GINECO), Paris, France;8. Cabrini Hospital, Department of Medical Oncology, Malvern, VIC, Australia;9. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland;10. Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan;11. The Royal Marsden NHS Foundation Trust, London, UK;12. The Institute of Cancer Research, London, UK;13. Gustave Roussy Cancer Campus, Villejuif, France;14. BC Cancer—Vancouver, Vancouver, BC, Canada;15. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea;p. Poznan University of Medical Sciences, Department of Oncology, Poznan, Poland;q. Center for Uterine Cancer, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea;r. Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA;s. Pfizer Oncology, Cambridge, MA, USA;t. Pfizer Oncology, San Diego, CA, USA;u. Pfizer, Global Biometrics and Data Management, Groton, CT, USA;v. Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA |
